Abstracts tagged "rheumatoid arthritis (RA) and tofacitinib"

Abstract Number: 1444 • 2019 ACR/ARP Annual Meeting
Tofacitinib in Patients with Rheumatoid Arthritis and Indicative of Depression And/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3b/4 Clinical Trials
Gustavo Citera¹, Rakesh Jain ², Fedra Irazoque ³, Renato Guzman ⁴, Hugo Madariaga ⁵, David Gruben ⁶, Lisy Wang ⁶, Lori Stockert ⁷, Ming-Ann Hsu ⁸, Karina Santana ⁹, Abbas Ebrahim ¹⁰ and Dario Ponce de Leon ¹¹, ¹Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ²Texas Tech University School of Medicine, Lubbock, TX, ³Hospital Angeles Mocel, San Miguel, Mexico, ⁴Fundación Universitaria Juan N. Corpas e IDEARG, Bogota, Colombia, ⁵Clínica del Sur, Arequipa, Peru, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Groton, ⁹Pfizer Inc, Mexico City, Mexico, ¹⁰Pfizer Inc, Collegeville, ¹¹Pfizer Inc, Lima, Peru
Background/Purpose: Depression and anxiety are common in patients (pts) with RA1 and can lead to reduced quality of life, functional capacity, and RA treatment response.2-4…
Abstract Number: 1338 • 2019 ACR/ARP Annual Meeting
Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start
Mojca Frank-Bertoncelj¹, Oliver Distler ², Tim Killeen ³, Kenneth Kwok ⁴, Lisy Wang ⁵, Caroline Ospelt ¹ and Adrian Ciurea ¹, ¹University Hospital Zürich, Zürich, Switzerland, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Pfizer AG, Zürich, Switzerland, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Despite systemic inflammatory cues, RA affects synovial joints variably. Tofacitinib is an oral JAK inhibitor for the treatment of RA. Previous post hoc analyses…
Abstract Number: 1373 • 2019 ACR/ARP Annual Meeting
Performance of CQR5 vs CQR19 in the Evaluation of Adherence to Tofacitinib in Daily Clinical Practice
Tatiana Barbich¹, Osvaldo Luis Cerda ², Emilce Schneeberger ³ and Gustavo Citera ⁴, ¹Instituto de Rehabilitación Psicofísica, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Instituto de Rehabilitacion Psicofisica, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ³Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: To evaluate the adherence to treatment with Tofacitinib in patients with Rheumatoid Arthritis (RA) using both versions of the self-questionnaire Compliance Questionnaire Rheumatology: CQR19…
Abstract Number: 1426 • 2019 ACR/ARP Annual Meeting
Impact of TNF Inhibitor Cycling with Adalimumab and Etanercept vs Switching to Tofacitinib
James Harnett¹, Timothy Smith ¹, John Woolcott ², David Gruben ³ and Christopher Murray ², ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Collegeville, PA, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. It was approved for RA by the US FDA in Nov 2012. TNFi…
Abstract Number: 580 • 2018 ACR/ARHP Annual Meeting
Clinical Effectiveness of Tofacitinib 11mg Once Daily (QD) Versus Tofacitinib 5mg Twice Daily (BID) in the Corrona US RA Registry
Stanley Cohen¹, Heather J Litman², Connie Chen³, Tatjana Lukic³, Ann Madsen³, Liza Takiya⁴, Kimberly J Dandreo², Taylor Blachley² and Jeffrey Greenberg², ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Corrona LLC, Waltham, MA, ³Pfizer Inc, New York, NY, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, originally approved at 5 mg twice daily (BID). In 2016, an extended-release…
Abstract Number: 581 • 2018 ACR/ARHP Annual Meeting
Comparative Analysis of Outcomes Among Patients with Rheumatoid Arthritis Initiating Tofacitinib in Combination with Oral MTX Who Discontinue, Interrupt, or Persist with MTX
Stanley Cohen¹, Boulos Haraoui², Jeffrey R. Curtis³, Timothy Smith⁴, John Woolcott⁵, David Gruben⁶, Christopher W Murray⁵, Noriko Iikuni⁴, Andrew Koenig⁵ and James Harnett⁴, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Institut de Rhumatologie de Montreal, Montreal, QC, Canada, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, in combination with MTX or other non‑biologic (nb)DMARDs, or as monotherapy. Two…
Abstract Number: 606 • 2018 ACR/ARHP Annual Meeting
Similiar Efficacy of Tofacinitib on Disease Activity in Rheumatoid Arthritis Patients with and without Previous Biologicals; Results from the Turkbio Regıstry
Berrin Zengin¹, Nevsun Inanc², Servet Akar³, Gerçek Can¹, Ediz Dalkiliç⁴, Abdurrahman Tufan⁵, Soner Senel⁶, Suleyman Serdar Koca⁷, Handan Yarkan¹, Yavuz Pehlivan⁸, Zeynep Erturk⁹, Berna Goker⁵, Haner Direskeneli², Merih Birlik¹, Nurullah Akkoc¹⁰ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ³Faculty of Medicine, Department of Rheumatology, Izmir Katip Celebi University, Izmir, Turkey, ⁴Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁵Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, ⁶Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ⁷Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ⁸Rheumatology, Uludag University, Faculty of Medicine, Bursa, Turkey, ⁹Rheumatology, Marmara University Faculty of Medicine, istanbul, Turkey, ¹⁰Rheumatology, İzmir, Turkey, İzmir, Turkey
Background/Purpose: Tofacitinib, a JAK3 inhibitor has been used to treat patients with rheumatoid arthritis (RA) in Turkey since 2015. The aim of this study was…
Abstract Number: 607 • 2018 ACR/ARHP Annual Meeting
Clinical and Functional Response to Tofacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from the ORAL Strategy Trial
Tsutomu Takeuchi¹, Josef S. Smolen², Roy Fleischmann³, Noriko Iikuni⁴, Haiyun Fan⁵, Koshika Soma⁶, Ermeg Akylbekova⁷ and Tomohiro Hirose⁸, ¹Keio University, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ³Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Groton, CT, ⁷IQVIA, Durham, NC, ⁸Pfizer Japan Inc, Tokyo, Japan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. ORAL Strategy (NCT02187055), a 12-month, global, Phase 3b/4 study, demonstrated that in…
Abstract Number: 685 • 2018 ACR/ARHP Annual Meeting
Changes in Key Laboratory Values with Tofacitinib 5mg BID Treatment in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
William FC Rigby¹, Gerd R. Burmester², Oliver FitzGerald³, Valderilio F Azevedo⁴, Peter Nash⁵, Thijs Hendrikx⁶, Daniela Graham⁷, Cunshan Wang⁷ and Thomas Jones⁶, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Charité – University Medicine Berlin, Berlin, Germany, ³Department of Rheumatology, St Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College, Dublin, Ireland, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵University of Queensland, Brisbane, Australia, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and rheumatoid arthritis (RA). In most countries where tofacitinib is…
Abstract Number: 1018 • 2018 ACR/ARHP Annual Meeting
Tofacitinib Impairs Monocyte-Derived Dendritic Cell Differentiation in Rheumatoid Arthritis and Psoriatic Arthritis.
Viviana Marzaioli¹, Mary Canavan¹, Achilleas Floudas¹, Siobhan C. Wade¹, Candice Low², Douglas J. Veale² and Ursula Fearon¹, ¹Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, ²Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland
Background/Purpose: Tofacinitib (Pfizer) is an oral Janus kinase inhibitor, recently approved for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Although its mechanism…
Abstract Number: 1515 • 2018 ACR/ARHP Annual Meeting
Malignancy in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim Analysis of All-Case Post-Marketing Surveillance
Naoto Tamura¹, Masataka Kuwana², Tatsuya Atsumi³, Syuji Takei⁴, Masayoshi Harigai⁵, Takao Fujii⁶, Hiroaki Matsuno⁷, Tsuneyo Mimori⁸, Shigeki Momohara⁹, Kazuhiko Yamamoto¹⁰, Yoshinari Takasaki¹¹, Kazuto Nomura¹², Yutaka Endo¹², Tomohiro Hirose¹², Yosuke Morishima¹², Naonobu Sugiyama¹², Noritoshi Yoshii¹² and Michiaki Takagi¹³, ¹Juntendo University, Tokyo, Japan, ²Nippon Medical School, Tokyo, Japan, ³Hokkaido University, Sapporo, Japan, ⁴Medical Center for Children, Kagoshima, Japan, ⁵Tokyo Women’s Medical University, Tokyo, Japan, ⁶Wakayama Medical University, Wakayama, Japan, ⁷Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ⁸Kyoto University, Kyoto, Japan, ⁹Hakkeikai Inc Medical Institution, Shizuoka, Japan, ¹⁰The University of Tokyo, Tokyo, Japan, ¹¹Juntendo Koshigaya Hospital, Juntendo University Faculty of Medicine, Saitama, Japan, ¹²Pfizer Japan Inc, Tokyo, Japan, ¹³Yamagata University Faculty of Medicine, Yamagata, Japan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The efficacy and safety of tofacitinib have been demonstrated in patients (pts)…
Abstract Number: 1516 • 2018 ACR/ARHP Annual Meeting
Infection Events in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim All-Case Post-Marketing Surveillance
Naoto Tamura¹, Masataka Kuwana², Tatsuya Atsumi³, Syuji Takei⁴, Masayoshi Harigai⁵, Takao Fujii⁶, Hiroaki Matsuno⁷, Tsuneyo Mimori⁸, Shigeki Momohara⁹, Kazuhiko Yamamoto¹⁰, Yoshinari Takasaki¹¹, Kazuto Nomura¹², Yutaka Endo¹², Tomohiro Hirose¹², Yosuke Morishima¹², Naonobu Sugiyama¹², Noritoshi Yoshii¹² and Michiaki Takagi¹³, ¹Juntendo University, Tokyo, Japan, ²Nippon Medical School, Tokyo, Japan, ³Hokkaido University, Sapporo, Japan, ⁴Medical Center for Children, Kagoshima, Japan, ⁵Tokyo Women’s Medical University, Tokyo, Japan, ⁶Wakayama Medical University, Wakayama, Japan, ⁷Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ⁸Kyoto University, Kyoto, Japan, ⁹Hakkeikai Inc Medical Institution, Shizuoka, Japan, ¹⁰The University of Tokyo, Tokyo, Japan, ¹¹Juntendo Koshigaya Hospital, Juntendo University Faculty of Medicine, Saitama, Japan, ¹²Pfizer Japan Inc, Tokyo, Japan, ¹³Yamagata University Faculty of Medicine, Yamagata, Japan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Previously, the efficacy and safety of tofacitinib were demonstrated in patients (pts)…
Abstract Number: 1527 • 2018 ACR/ARHP Annual Meeting
Tofacitinib Improves Left Ventricular Mass and Cardiac Output in Rheumatoid Arthritis Patients with Chronic Heart Failure
Kensuke Kume¹, Kanzo Amano², Susumu Yamada³, Toshikatsu Kanazawa³ and Kazuhiko Hatta⁴, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²rheumatology., hiroshima clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴Rheumatology, Hatta Clinic, Kure, Japan
Background/Purpose: Rheumatologists need to develop primary and secondary prevention strategies for cardiovascular disease (CVD) in rheumatoid arthritis (RA) patients. We reported tofacitinib (Tofa) (with or…
Abstract Number: 1531 • 2018 ACR/ARHP Annual Meeting
Tofacitinib Show Similar Retention When Used with and without Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Jacques Brown², Boulos Haraoui¹, Frédéric Massicotte¹, Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Angèle Turcotte², Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Rheumatology, Centre de l'Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: Tofacitinib (TOFA), a targeted synthetic DMARD has recently appeared on the Canadian market. It is an oral agent, targeting the JAK 1 and JAK…
Abstract Number: 1547 • 2018 ACR/ARHP Annual Meeting
Impact of Obesity on Drug Survival of Tofacitinib in Patients with Rheumatoid Arthritis: Analysis from the Turkbio Registry
Hakan Babaoglu¹, Berna Goker¹, Nevsun İnanç², Merih Birlik³, Suleyman Serdar Koca⁴, Ayse Cefle⁵, Ediz Dalkiliç⁶, Abdurrahman Tufan¹, Sema Yilmaz⁷, Soner Senel⁸, Servet Akar⁹, Nurullah Akkoc¹⁰, Fatos Onen³ and Ummugulsum Gazel¹¹, ¹Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Marmara University faculty of Medicine, İstanbul, Turkey, ³Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ⁴Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ⁵Rheumatology, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey, ⁶Department of Internal Medicine, Division of Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey, ⁷Department of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, ⁸Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ⁹Department of Internal Medicine, Division of Rheumatology,, Izmir Katip Çelebi University Faculty of Medicine, Izmir, Turkey, ¹⁰Rheumatology, İzmir, Turkey, İzmir, Turkey, ¹¹Rheumatology, Marmara University faculty of Medicine, Istanbul, Turkey
Background/Purpose: Several previous reports suggest that obesity impairs the effectiveness and drug survival of anti-TNF-α agents in rheumatoid arthritis (RA). The aim of the study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].